Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.56 |
| ▸ | F2 | P00734 | 3/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | IL1RN | P18510 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35030 | 0.98 | F2 (0.57) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL29792725 | 0.98 | F2 (0.57) | F2PRSS1PRSS2PRSS3CA1 | |
| Methane SCHEMBL28888703 | 0.96 | F2 (0.56) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL1729812 | 0.91 | CA1 (0.51) | F2PRSS1PRSS2PRSS3CA1 | |
| Pyridine SCHEMBL9306571 | 0.88 | CYP2C19 (0.50) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL28122811 | 0.85 | CA1 (0.54) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL6888383 | 0.84 | LMNA (0.54) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL9822576 | 0.83 | TDP1 (0.61) | CA1CA2TSHRALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL11742111 | 0.82 | LCK (0.61) | F2PRSS1PRSS2PRSS3CA1 | |
| Hydrochloric Acid SCHEMBL10586127 | 0.82 | LCK (0.61) | F2PRSS1PRSS2PRSS3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590948-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | Wyeth LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2012004748-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | WYETH LLC (US) | 2012-01-12 | — | — | WO | disclosed |
| US-7534780-B2 | Estradiol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20050288267-A1 | Estradiol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | disclosed |
| US-20050282793-A1 | Steroid prodrugs with androgenic action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-22 | — | — | US | disclosed |
| US-20050277625-A1 | Estriol and estetrol prodrugs | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-12-15 | — | — | US | disclosed |
| EP-0782042-B1 | Hydrazine compound and silver halide photographic photosensitive material comprising the same | FUJI PHOTO FILM CO LTD (JP) | 1999-12-01 | — | — | EP | disclosed |
| US-5935757-A | HIGH COLOR DEVELOPING SENSITIVITY AND EXCELLENT STORABILITY. USING AN ESTER- OR AMIDE CONTAINING SULFOAMIDOBENZENE IN A LAYER CONTAINING A DIAZONIUM SALT AND A REACTIVE COUPLER | FUJI PHOTO FILM CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| US-5789139-A | STORAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0782042-A2 | Hydrazine compound and silver halide photographic photosensitive material comprising the same | FUJI PHOTO FILM CO., LTD. (JP) | 1997-07-02 | — | — | EP | disclosed |
| US-4956456-A | POLYACRYLONITRILE FIBERS, DACRON\" FIBERS | FUJI PHOTO FILM CO., LTD. (JP) | 1990-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288267-A1 | Estradiol prodrugs | CYP19A1, ESR1, HSD17B11 | CA2 2551/4885F2 305/4885PRSS1 1232/4885 |
| US-20050282793-A1 | Steroid prodrugs with androgenic action | CYP21A2, CYP17A1, NR5A1 | CA2 2329/4885F2 1408/4885PRSS1 641/4885 |
| US-20050277625-A1 | Estriol and estetrol prodrugs | HSD17B11, CYP19A1, ESR1 | CA2 3004/4885F2 324/4885PRSS1 781/4885 |
| US-20120010205-A1 | NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS | NR1H2, NR1H3, NR1H4 | CA2 4719/4885F2 3780/4885PRSS1 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.